NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,475.92 +268.82 (+1.48%) CRUDE OIL
78.49 +0.38 (+0.49%) GOLD FUTURES
2,311.00 +2.40 (+0.10%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
50,955.62 +136.95 (+0.27%)
TG Therapeutics, Inc. (0VGI.L)
| Previous close | 16.44 |
| Open | 16.81 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 16.18 - 16.97 |
| 52-week range | 6.47 - 35.58 |
| Volume | |
| Avg. volume | 12,871 |
| Market cap | 14.559M |
| Beta (5Y monthly) | 2.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan
- GlobeNewswire
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ETNEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U
- GlobeNewswire
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutic
